3 days in-person. 3 days virtually.
March 20–22, 2023 | Basel, SwitzerlandMarch 28–30, 2023 | Digital Carole NuechterleinHead, Roche Venture Fund at F.Hoffmann-La Roche
Profile
Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.
She currently serves as a director at Aligos Therapeutics, Arch Oncology, CiVi Biopharma, Entrada Therapeutics, Enthera Pharmaecuticals, Mission Therapeutics, Second Genome and Vivet Therapeutics. She was formerly a director at Allakos and AveXis.
She has a BA from Valparaiso University and a JD from University of Michigan.
More information on the Roche Venture Fund can be found at www.venturefund.roche.com.
Agenda Sessions
Shifting approaches to investment and how investors collaborate
, 15:30View Session